Contents
On this page
- The question a payer is asking
- Five evaluations, five questions
- Perspective and time horizon: chosen before the data, decisive for the answer
- A worked radiotherapy example, read properly
- The global access case, and why it is a different argument
- CHEERS 2022: 28 items, and the ones that get missed
- Turning manufacturer clinical data into economic evidence
- Writing the evaluation so it can be assessed
- What this evidence base does not settle
- Take-home message
- How to apply this to your study
- Common questions
Academy · Research Writing · RT device cost-effectiveness
Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads
A cost-effectiveness analysis without a stated perspective and time horizon is not a weak analysis — it is an uninterpretable one, because the same device can be cost-effective from one perspective and not from another. CHEERS 2022 sets out 28 items that a health economic evaluation is expected to report, and perspective and horizon are among the ones most often left implicit.
Regulatory clearance tells a hospital that a device may be sold. It tells the person signing the purchase order nothing about whether to buy it. That second question is answered by a different evidence package with different rules, a different comparator and a different audience — and radiotherapy device manufacturers routinely arrive at it having built a clinical dossier that cannot be converted into one. This page covers what a health economic evaluation has to contain, which choices determine the result before any data are analysed, and how CHEERS 2022 expects it to be reported.
What you will learn
- Which question each evaluation type answers — cost-effectiveness, cost-utility, cost-minimisation, cost-benefit, budget impact — and when each is the wrong one
- Why perspective and time horizon determine the result, and how to choose them defensibly
- How to read an incremental cost-effectiveness ratio, using a published radiotherapy example with an ICER of $1,120 per life-year gained
- The difference between a life-year and a quality-adjusted life-year, and why it changes which analysis you have run
- What the 28 items of CHEERS 2022 ask for, and which ones manufacturers’ submissions most often miss
- Why a global access argument is not a product-level value argument, and how to keep the two apart
What to unlearn
- “Cost-effectiveness means cheaper.” It means the additional health gained is worth the additional cost. In Mitera and colleagues’ radiotherapy analysis the more effective option was also the more expensive one, at $8,042 against $6,886 in mean costs — and it was still the cost-effective choice.
- “An ICER is a property of the technology.” It is a property of the technology, the comparator, the population, the perspective, the horizon, the discount rate and the setting. Change any one and the number changes. That is why CHEERS 2022 asks you to report all of them.
- “A cost-effectiveness analysis and a cost-utility analysis are the same thing.” Cost-utility uses quality-adjusted life-years. Mitera and colleagues reported cost per life-year gained, which is not quality-adjusted — a difference that matters when the two treatments have different toxicity profiles.
- “CHEERS is a methods standard.” CHEERS 2022 is a reporting guideline. It tells you what a reader needs to see; it does not tell you whether your model structure or your utility source was appropriate. Reporting completely does not make a flawed analysis valid.
- “Regulatory approval evidence will serve for market access.” A regulatory submission establishes safety and performance against a defined benchmark. A payer submission asks whether the health gained is worth the additional cost against the comparator actually in use locally. The comparator alone is often different.
The question a payer is asking
A hospital, a regional purchaser or a national technology assessment agency is not asking whether your linear accelerator, planning system or motion-management device works. They are asking whether the additional health their population gains from it is worth the additional resources it consumes, relative to whatever they are doing now. That is a comparative and incremental question, and almost everything that makes health economic evaluation difficult follows from those two words.
Comparative means the comparator matters as much as the intervention. The relevant comparator is current practice in the decision-maker’s setting, not the comparator that made your clinical trial feasible. If conformal radiotherapy is the local standard and your analysis compares against a technique that is no longer used, the result is not usable however well it was conducted.
Incremental means the output is a ratio of differences: the difference in cost divided by the difference in effect. It is not a cost per patient, not a return on investment, and not a saving. The commonest error we see in manufacturer-authored economic material is a document that computes a total cost of ownership and calls it a cost-effectiveness analysis. Those are both legitimate documents, and they answer different questions for different readers.
The development economics behind the device shape how this is received. Wouters and colleagues, in JAMA, estimated median capitalised research and development investment per new medicine at $1,141.7 million (95% CI $888.1–$1,480.8 million) 20. That is a pharmaceutical figure, not a device one, and it is cited here only as the order of magnitude a payer has in mind when a manufacturer explains that development was expensive 20. Development cost is not an input to a cost-effectiveness analysis. Price is.
Five evaluations, five questions
The family of economic evaluations is small, and choosing the wrong member is a more common failure than executing the chosen one badly. Cost-minimisation analysis applies only where the effects are genuinely equivalent — and “non-inferior on the primary endpoint” is not the same as equivalent, so this is used more often than it is justified. Cost-effectiveness analysis expresses the result in natural units: cost per life-year gained, cost per local recurrence avoided, cost per fraction delivered. Cost-utility analysis expresses it in quality-adjusted life-years, which allows comparison across disease areas and is what most national agencies prefer. Cost-benefit analysis monetises the health effect itself, which is rare in health technology assessment and common in public infrastructure appraisal. Budget impact analysis asks a different question entirely — what the total spend consequence is over a planning period — and a purchaser frequently wants both it and a cost-utility analysis, because an intervention can be cost-effective and unaffordable at once.
For radiotherapy devices the choice between cost-effectiveness and cost-utility is usually the live one, and it turns on whether the techniques being compared differ in toxicity or in treatment burden. If they do, a life-year-based analysis will miss part of the difference. Fewer fractions is a real patient-level benefit that does not appear in survival at all.
Which evaluation answers which question
| Evaluation | Output | The question it answers | When it is the wrong choice |
|---|---|---|---|
| Cost-minimisation | Difference in cost | Which option costs less, where the health effects are equivalent | Whenever effects are not genuinely equivalent — non-inferiority on one endpoint is not equivalence |
| Cost-effectiveness | Cost per natural unit (life-year gained, recurrence avoided) | Is the extra health worth the extra cost, in clinically meaningful units | When the options differ in toxicity or treatment burden, which natural units do not capture |
| Cost-utility | Cost per quality-adjusted life-year | Is the extra health worth the extra cost, comparably across disease areas | When no defensible utility source exists for the health states, and the result would be driven by an arbitrary choice |
| Cost-benefit | Net monetary benefit | Does the monetised value of the health gain exceed the cost | Where monetising health is unacceptable to the audience, which is most health technology assessment |
| Budget impact | Total spend over a planning period | Can this be afforded, and what is displaced | As a substitute for cost-effectiveness — it answers affordability, not value, and purchasers often want both |
Standard definitions as used in the health economic evaluation literature; reporting expectations for each follow the CHEERS 2022 statement (Husereau and colleagues, BMJ) and its explanation and elaboration paper (Value in Health).
Perspective and time horizon: chosen before the data, decisive for the answer
Perspective determines which costs and which consequences count. A public payer perspective counts costs falling on the health system. A healthcare sector perspective may include costs borne by other providers. A societal perspective adds productivity losses, patient and carer time, and travel. For radiotherapy the choice is not academic: a hypofractionated regimen that delivers treatment in five visits rather than twenty shifts a large cost from the patient and their family to no one — which is to say it disappears from a payer analysis and appears in a societal one. Report the perspective, and if you believe the societal case is stronger, report both and say which is the base case.
Time horizon determines how much of the consequence you capture. It should be long enough to include all differences in cost and effect between the options; for an oncology intervention affecting survival, that generally means a lifetime horizon, which in turn means modelling beyond the trial follow-up and discounting future costs and effects. A one-year horizon on a device that changes five-year survival is not a conservative choice. It is the wrong analysis.
These two choices interact with the comparator and the discount rate to produce the number, and none of them are discoverable from the result. That is precisely why they are reporting items. Our page on health economics in clinical trials covers how to collect the resource-use data prospectively so these choices remain open to you later; deciding the perspective after the trial has closed usually means discovering that the data for the one you wanted were never collected.
A worked radiotherapy example, read properly
Mitera and colleagues, in JCO Oncology Practice, compared conventional radiotherapy with stereotactic body radiotherapy in patients with surgically ineligible stage I non-small-cell lung cancer 25. The analysis covered 168 patients, 50 treated conventionally and 118 with stereotactic body radiotherapy 25. Mean overall survival was 2.83 years with conventional treatment and 3.86 years with stereotactic treatment. Mean costs were $6,886 and $8,042 respectively. The incremental cost-effectiveness ratio was $1,120 per life-year gained, from the public payer perspective.
Read that structure rather than the number. The more effective option cost more, which is the normal case and the reason the ratio exists. The denominator is life-years, not quality-adjusted life-years, so differences in toxicity and treatment burden between the two techniques are not captured — and since stereotactic treatment is delivered in far fewer fractions, a quality-adjusted analysis might well have been more favourable still. The perspective is the public payer, so patient and family costs are outside it, which again would tend to favour the fewer-fraction option if included. And the costs are in the currency, year and health system of the original analysis, which is why an ICER cannot be lifted into another jurisdiction without being rebuilt.
A manufacturer reading this should take two lessons. First, a modest ICER in natural units can be a strong argument, and it does not require a complex model. Second, every qualifier in the paragraph above — perspective, denominator, setting, currency year — is a CHEERS reporting item, and the analysis is interpretable precisely because they are stated 19.
168 patients with surgically ineligible stage I non-small-cell lung cancer (50 conventional, 118 stereotactic body radiotherapy). Source: Mitera G, Swaminath A, Rudoler D, et al. Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer. JCO Oncology Practice. Costs are in the currency and year of the original analysis; the denominator is life-years, not quality-adjusted life-years.
The global access case, and why it is a different argument
Radiotherapy has an unusually strong macroeconomic case, and manufacturers are tempted to use it as a product argument. Atun and colleagues, in The Lancet Oncology, estimated that 12 million patients could benefit from radiotherapy by 2035, while only 40–60% of patients who need radiotherapy currently have access to it and 40 countries have no radiotherapy facilities at all 24. Their investment analysis found that scaling up global radiotherapy capacity would cost US$97 billion with efficiency improvements, or US$184 billion without them, and would return 27 million life years and US$278–365 billion over 20 years 24.
Those are powerful figures and they are about capacity, not about products 24. They support an argument for investing in radiotherapy infrastructure; they do not support an argument that a particular accelerator, planning system or immobilisation device is good value against the alternative device a hospital is also considering. Using the first to answer the second is the most common category error in this field, and health technology assessment reviewers recognise it immediately.
Where the access data are genuinely useful to a manufacturer is in framing the decision problem for low- and middle-income settings, where the relevant comparator may be no radiotherapy rather than a different machine, and where the cost structure — staffing, maintenance, uptime, power — dominates the capital price 24. An evaluation built for a high-income single-payer system will not transfer, and saying so is more credible than implying it will.
Global radiotherapy capacity and the investment case; scale-up was costed at US$97 billion with efficiency improvements or US$184 billion without, returning 27 million life years and US$278–365 billion over 20 years. Source: Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. The Lancet Oncology. These are capacity figures and do not support a claim about any individual device.
CHEERS 2022: 28 items, and the ones that get missed
Husereau and colleagues published the CHEERS 2022 statement in BMJ, with the explanation and elaboration paper in Value in Health, setting out a 28-item checklist for reporting health economic evaluations 18,19. It is a reporting guideline in the same family as CONSORT and PRISMA: it tells you what a reader must be able to find, not whether your methods were right 19. Both documents are worth having open while you write, because the explanation and elaboration paper gives the reasoning and examples for each item 18.
In our experience of reviewing manufacturer-authored evaluations, the items that go missing cluster in a predictable way. The perspective is stated vaguely or not at all. The time horizon is given without a justification for its length. The comparator is described as “standard of care” without saying what that was in the setting modelled. The source of health state utility values is not named, which matters because utilities drive a cost-utility result as strongly as costs do 18. The discount rate is applied but not reported, or reported but not applied to effects. Uncertainty is addressed with a handful of one-way sensitivity analyses rather than a probabilistic analysis, and heterogeneity across subgroups is not addressed at all. And the funding and conflict-of-interest statement is thin, which for a manufacturer-sponsored analysis is the item a sceptical reader checks first.
Our reporting guidelines overview covers how CHEERS sits alongside the other major checklists, and our biostatistics team handles the probabilistic analysis and value-of-information work that the uncertainty items call for.
Turning manufacturer clinical data into economic evidence
Most radiotherapy device manufacturers hold more usable data than they realise and less than they need. Treatment planning records, delivery logs, quality assurance records and service data describe resource use in considerable detail. What is usually missing is the three things an evaluation needs most: a comparator arm treated in the same setting, outcomes measured over a horizon long enough to matter, and health state utilities.
Three routes out of that are worth considering, and they differ in cost and credibility. The first is to embed economic data collection in a prospective study, which is the strongest option and requires deciding the perspective in advance so the right resource categories are captured. The second is to build a model populated from published effectiveness evidence and local cost data, which is the standard approach for technology assessment submissions and is only as good as the evidence identified — so the identification should be a documented systematic review, not a selective citation list. The third is registry or routine data analysis, which is attractive for devices but carries confounding by indication that is difficult to resolve, since clinicians select patients for advanced techniques for reasons that also predict outcome.
Whichever route, the regulatory and the economic evidence programmes should be designed together even though they answer to different audiences. The clinical evidence expectations that devices now face in Europe make this easier to justify, and we have set those out in regulatory and ethical challenges for medical devices 16. One prospective study, designed once, can serve both if the economic endpoints are specified at protocol stage. Retrofitted, it serves neither well.
Writing the evaluation so it can be assessed
The difference between an economic write-up that a technology assessment reviewer can work with and one that gets returned is rarely the modelling. It is whether the reader can identify the decision problem: who is deciding, for which population, between what and what, over what horizon, counting whose costs. The weak version buries all of that and leads with the result.
The same analysis, unreportable versus CHEERS-compliant
Missing the decision problem
A cost-effectiveness analysis was performed comparing the new stereotactic delivery platform with standard radiotherapy. The new platform was found to be cost-effective, with an incremental cost-effectiveness ratio of $1,120 per life-year gained. Sensitivity analyses confirmed the robustness of the result. The platform therefore represents good value for money for healthcare systems.
Whose costs? No perspective, so the reader cannot tell what was counted.
Over what period? No time horizon, and no discounting implied either way.
Compared with what, exactly? “Standard radiotherapy” varies between countries and between centres.
Life-years or QALYs? Stated here, but with no acknowledgement of what the choice leaves out.
Robust in what sense? “Sensitivity analyses confirmed” names no method and no parameter.
Cost-effective against which threshold? Asserted, which is the claim a reviewer is least willing to accept from a sponsor.
States perspective, horizon, comparator and uncertainty
We conducted a cost-effectiveness analysis comparing stereotactic body radiotherapy with conventional fractionated radiotherapy in patients with surgically ineligible stage I non-small-cell lung cancer, from the public payer perspective in a single-payer system, over a lifetime horizon, with costs and effects discounted at the rate specified by the national guideline and reported in that guideline’s reference year. The comparator was conventional fractionated radiotherapy as delivered in the participating centres during the study period, which we describe in Section 2.2 because practice varies. Effectiveness was taken from the cohort described above; the outcome is life-years gained, not quality-adjusted life-years, because no utility source specific to these toxicity profiles was available — a limitation that would, if anything, understate the advantage of the fewer-fraction regimen. The incremental cost-effectiveness ratio was $1,120 per life-year gained. Uncertainty was characterised by probabilistic analysis with the resulting cost-effectiveness acceptability curve in Figure 3, and by one-way analyses on the parameters to which the result was most sensitive, which were equipment utilisation rate and fraction cost. We do not state whether the result is cost-effective: that depends on the threshold applied by the deciding body, which differs between jurisdictions and is not published by all of them. Funding and the role of the sponsor are declared in full at Section 6.
Perspective, horizon, discount rate and reference year are all stated, so the result is interpretable and reproducible.
The comparator is described as actually delivered, with a cross-reference, rather than named generically.
The outcome unit is stated with its limitation, and the direction of the resulting bias is given.
Uncertainty is probabilistic, with the influential parameters named and an acceptability curve provided.
The cost-effectiveness verdict is handed to the deciding body along with the reason — which is both correct and more persuasive than asserting it.
Sponsor role is declared prominently, which is where a sceptical reader looks first.
The analysis is identical in both versions. The second is longer by one paragraph and converts an unusable claim into an assessable submission, because every element of the decision problem is on the page. Most of the additions are CHEERS 2022 items, which is the practical argument for drafting against the 28-item checklist rather than checking against it at the end.
What this evidence base does not settle
Three limits are worth stating. First, cost-effectiveness thresholds are not uniform and some agencies do not publish one at all, so “cost-effective” is a jurisdiction-specific judgement rather than a property of your ICER. An analysis that declares a result cost-effective without naming the threshold applied and its source has skipped the step the reader cares about.
Second, health state utilities for radiotherapy toxicity and treatment burden are sparse and inconsistently derived, which means cost-utility results in this field are often sensitive to a utility source chosen from a small set. That sensitivity should be shown, not smoothed.
Third, device-specific long-term outcome evidence is weaker than the installed base suggests. Hoogervorst and colleagues, in the International Journal of Health Policy and Management, reviewed European cardiovascular and orthopaedic registries for regulatory evaluation of device safety and performance and found reporting of registry structure and methodology highly variable — a finding from other device domains, but a fair warning about leaning on registry data for long-horizon device modelling 14. Where your model extrapolates beyond observed data, say how far and show what happens if the extrapolation is wrong.
Take-home message
Take-home message
A cost-effectiveness analysis is a statement about a decision problem, not about a device. Fix the decision problem first: who decides, for which population, against which comparator as actually used in their setting, from which perspective, over which horizon. Those choices determine the result, so CHEERS 2022 requires all of them to be reported, across 28 items. Mitera and colleagues’ radiotherapy analysis is instructive because it is simple and fully specified: $1,120 per life-year gained, from the public payer perspective, with life-years rather than quality-adjusted life-years as the denominator. Keep the global capacity argument — 12 million patients who could benefit by 2035, 40–60% current access, 40 countries with no facilities — separate from your product-level value argument, because reviewers will separate them for you.
How to apply this to your study
How to apply this to your own study
- Write the decision problem in one paragraph before anything else. Decision-maker, population, intervention, comparator as actually used in their setting, perspective, horizon. If you cannot write it, you do not yet have an analysis.
- Choose the comparator from local practice, not from your trial. A comparator that is no longer used makes a well-conducted analysis unusable.
- Set the time horizon long enough to capture every difference in cost and effect. For survival-modifying oncology interventions that generally means a lifetime horizon, with discounting and an explicit extrapolation assumption.
- Decide whether you need quality-adjusted life-years, and if you do, name the utility source now. If no defensible source exists for your health states, say so and run the natural-unit analysis rather than inventing utilities.
- Draft against the 28 CHEERS 2022 items rather than checking against them afterwards. Perspective, horizon justification, comparator description, utility source, discount rate and sponsor role are the ones most often missing.
- Characterise uncertainty probabilistically and report which parameters drive the result. A handful of one-way analyses and the phrase “robust” will not satisfy a technology assessment reviewer.
- Do not declare your own result cost-effective. Name the threshold a deciding body would apply, cite its source, and let the comparison be made — some agencies publish no threshold at all.
- Specify economic endpoints at protocol stage, and resource-use collection with them. Perspective decided after the trial closes usually means the data for the perspective you wanted were never collected.
- Keep the capacity argument and the product argument in separate documents. Global access figures support investment in radiotherapy; they do not support a claim about one platform against another.
Common questions
Both divide the difference in cost by the difference in effect; they differ in the unit of effect. Cost-effectiveness analysis uses a natural clinical unit — cost per life-year gained, cost per local recurrence avoided. Cost-utility analysis uses quality-adjusted life-years, which weight survival time by health-related quality of life and so allow comparison across disease areas. Most national technology assessment agencies prefer cost-utility for that reason. The choice matters when the options differ in toxicity or treatment burden: Mitera and colleagues, in JCO Oncology Practice, reported $1,120 per life-year gained for stereotactic body radiotherapy against conventional treatment, a denominator that does not capture the benefit of delivering treatment in far fewer fractions.
Because it determines which costs and consequences are counted at all. A public payer perspective includes costs falling on the health system; a societal perspective adds productivity losses, patient and carer time, and travel. In radiotherapy that distinction is large. A hypofractionated regimen replacing twenty visits with five removes a substantial burden from patients and families, and that saving is invisible in a payer analysis and visible in a societal one. Neither is wrong; they answer different questions. CHEERS 2022 requires the perspective to be stated and justified, and if you believe the societal case is materially stronger, the defensible approach is to report both and nominate one as the base case.
Long enough that no difference in cost or effect between the options falls outside it. For an intervention that changes survival, that generally means a lifetime horizon, which commits you to modelling beyond observed follow-up and to discounting future costs and effects at the rate your target jurisdiction specifies. Shortening the horizon is not a conservative simplification — it systematically favours whichever option has its costs later and its benefits earlier, which is usually the comparator. If your data do not reach that far, the honest approach is to model the extrapolation explicitly, state the assumption, and show in sensitivity analysis what happens when it fails.
CHEERS 2022, published by Husereau and colleagues in BMJ with an explanation and elaboration paper in Value in Health, is a 28-item reporting checklist for health economic evaluations. It covers the title and abstract, the background and objectives, the decision problem including population, setting, comparators, perspective, time horizon and discount rate, the sources and measurement of effectiveness, resource use, costs and health state utilities, the analytic methods including how uncertainty and heterogeneity were handled, the results, a discussion of limitations and generalisability, and funding and conflicts of interest. It is a reporting guideline, not a methods guideline: complete reporting does not make a poorly specified analysis valid, but incomplete reporting makes a good one unassessable.
No, and trying is counterproductive. Atun and colleagues, in The Lancet Oncology, estimated that 12 million patients could benefit from radiotherapy by 2035, that only 40–60% of those needing it currently have access, that 40 countries have no radiotherapy facilities, and that global scale-up costing US$97 billion with efficiency improvements would return 27 million life years and US$278–365 billion over 20 years. Those figures make the case for investing in radiotherapy capacity. They say nothing about whether your platform is better value than the one a hospital is also considering, which is the question a purchaser is asking. Reviewers recognise the substitution, and it costs credibility elsewhere in the submission.
Usually not without additional work, because the two submissions answer to different questions. A regulatory submission establishes safety and performance against a defined benchmark; a payer submission asks whether the incremental health gain justifies the incremental cost against the comparator in local use. The comparator is often different, the outcome a payer cares about is often further downstream than the regulatory endpoint, the horizon is longer, and resource use and health state utilities are rarely collected in a regulatory study at all. The efficient answer is to design both programmes together and specify economic endpoints at protocol stage, so one prospective study can serve both audiences.
It is attractive and it has a specific weakness. Clinicians select patients for advanced radiotherapy techniques for reasons — performance status, tumour location, comorbidity — that also predict outcome, so confounding by indication is structural rather than incidental, and standard adjustment rarely resolves it to a reviewer’s satisfaction. Data quality is a second issue: Hoogervorst and colleagues, in the International Journal of Health Policy and Management, found reporting of structure and methodology highly variable across European cardiovascular and orthopaedic registries. Registry analysis is defensible as supporting evidence, or where the alternative is nothing, provided the confounding is addressed openly rather than adjusted away silently.
The deciding body, against a threshold it sets, and the thresholds are not uniform — some agencies publish one, some apply a range, and some do not publish any. That is why an analysis should report its ICER and the threshold it is being compared against, with the source, rather than asserting cost-effectiveness as a finding. For a manufacturer this is also tactically better: a submission that hands the judgement to the reader, having given them everything needed to make it, reads as more credible than one that announces the verdict. Confirm the applicable threshold and reference case with the agency’s own methods guide for each market.
References and sources
- U.S. Food and Drug Administration. Container Closure Systems for Human Drugs and Biological Products (draft guidance). U.S. Food and Drug Administration. 2026. read 9 October 2026. packagingdigest.com
- U.S. Food and Drug Administration (CDRH, CBER). Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". U.S. Food and Drug Administration. 2023. read 9 October 2026. fda.gov
- U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Carollo M, Cristini I, Crisafulli S, Fontana A, Forti A, Lanaro A, Maccarrone F, Zerio M, Piccoli L, Poluzzi E, Onder G, Trifiro G. Evaluating the impact of medication review and deprescribing on prescribing appropriateness and clinical outcomes in older people residing in long-term care facilities: a systematic review and meta-analysis. 2026. doi:10.1093/ageing/afag084 read 9 October 2026. doi.org/10.1093/ageing/afag084
- Daniel SA, Suya Prem Anand P, Jesuarockiam N, Tabrej K, Shabir Hussain K. Advancement in biomedical implant materials-a mini review. Frontiers in Bioengineering and Biotechnology. 2024;12. doi:10.3389/fbioe.2024.1400918 read 9 October 2026. doi.org/10.3389/fbioe.2024.1400918
- Ginn SL, Mandwie M, Alexander IE, Edelstein M, Abedi MR. Gene therapy clinical trials worldwide to 2023-an update. The Journal of Gene Medicine. 2024;26(8):e3721. doi:10.1002/jgm.3721 read 9 October 2026. doi.org/10.1002/jgm.3721
- Metuh P, Petersen PM, Ou Y. Recent Advances in Wireless Optoelectronic Biomedical Implants. Laser & Photonics Reviews. 2024;18(12):2300752. doi:10.1002/lpor.202300752 read 9 October 2026. doi.org/10.1002/lpor.202300752
- Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. International Journal of Pharmacy Practice. 2023;31(4):349-368. doi:10.1093/ijpp/riad025 read 9 October 2026. doi.org/10.1093/ijpp/riad025
- Everhart AO, Sen S, Stern AD, et al. Association between regulatory submission characteristics and recalls of medical devices receiving 510(k) clearance. JAMA. 2023;329:144-156. read 9 October 2026. tctmd.com
- Al-Zyoud W, Haddadin D, Hasan SA, Jaradat H, Kanoun O. Biocompatibility Testing for Implants: A Novel Tool for Selection and Characterization. Materials. 2023;16(21):6881. doi:10.3390/ma16216881 read 9 October 2026. doi.org/10.3390/ma16216881
- Shchaslyvyi AY, Antonenko SV, Tesliuk MG, Telegeev GD. Current State of Human Gene Therapy: Approved Products and Vectors. Pharmaceuticals. 2023;16(10):1416. doi:10.3390/ph16101416 read 9 October 2026. doi.org/10.3390/ph16101416
- Deprescribing Interventions for Older Patients: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2023. doi:10.1016/j.jamda.2023.07.016 read 9 October 2026. doi.org/10.1016/j.jamda.2023.07.016
- Hoogervorst LA, Geurkink TH, Lubbeke A, et al. Quality and Utility of European Cardiovascular and Orthopaedic Registries for the Regulatory Evaluation of Medical Device Safety and Performance Across the Implant Lifecycle: A Systematic Review. International Journal of Health Policy and Management. 2023;12(1):1-11. doi:10.34172/ijhpm.2023.7648 read 9 October 2026. doi.org/10.34172/ijhpm.2023.7648
- Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Therapy. 2023;30(10-11):738-746. doi:10.1038/s41434-023-00390-5 read 9 October 2026. doi.org/10.1038/s41434-023-00390-5
- Kearney B, McDermott O. The Challenges for Manufacturers of the Increased Clinical Evaluation in the European Medical Device Regulations: A Quantitative Study. Therapeutic Innovation & Regulatory Science. 2023. doi:10.1007/s43441-023-00527-z read 9 October 2026. doi.org/10.1007/s43441-023-00527-z
- Kadakia KT, Dhruva SS, Caraballo C, et al. Use of recalled devices in new device authorizations under the US Food and Drug Administration's 510(k) pathway and risk of subsequent recalls. JAMA. 2023;329:136-143. read 9 October 2026. tctmd.com
- Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Explanation and Elaboration: A report of the ISPOR CHEERS II Good Practices Task Force. Value in Health. 2022;25(1):10-31. read 9 October 2026. ispor.org
- Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. BMJ. 2022;376:e067975. read 9 October 2026. cris.iucc.ac.il
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
- Yu TTL, Gupta P, Ronfard V, Vertes AA, Bayon Y. Recent Progress in European Advanced Therapy Medicinal Products and Beyond. Frontiers in Bioengineering and Biotechnology. 2018;6:130. doi:10.3389/fbioe.2018.00130 read 9 October 2026. doi.org/10.3389/fbioe.2018.00130
- Kang CW, Fang FZ. State of the art of bioimplants manufacturing: part I. Advances in Manufacturing. 2018;6:20-40. doi:10.1007/s40436-017-0207-4 read 9 October 2026. doi.org/10.1007/s40436-017-0207-4
- Muskens IS, Gupta S, Hulsbergen A, Moojen WA, Broekman MLD. Introduction of Novel Medical Devices in Surgery: Ethical Challenges of Current Oversight and Regulation. Journal of American College of Surgeons. 2017;225:558-565. read 9 October 2026. scholarlypublications.universiteitleiden.nl
- Atun R, Jaffray DA, Barton MB, et al. Expanding global access to radiotherapy. The Lancet Oncology. 2015;16(10). read 9 October 2026. oncology-central.com
- Mitera G, Swaminath A, Rudoler D, Seereeram C, Giuliani M, Leighl N, Gutierrez E, Dobrow MJ, Coyte PC, Yung T. Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer. JCO Oncology Practice. 2014;10(3):e130-e136. doi:10.1200/jop.2013.001206 read 9 October 2026. doi.org/10.1200/jop.2013.001206
- Johnson J, Rogers W. Innovative surgery: The ethical challenges. Journal of Medical Ethics. 2012;38(1):9-12. doi:10.1136/jme.2010.042150 read 9 October 2026. doi.org/10.1136/jme.2010.042150
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads. Pubrica. https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/
Pubrica Academy. “Cost-Effectiveness Evidence for Radiotherapy Device Manufacturers: What a Payer Actually Reads.” Pubrica, 9 Oct. 2026, pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/.
Pubrica Academy (2026) Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads. Pubrica. Available at: https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/ (Accessed: 15 October 2026).
Pubrica Academy. “Cost-Effectiveness Evidence for Radiotherapy Device Manufacturers: What a Payer Actually Reads.” Pubrica. October 9, 2026. https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/
Pubrica Academy, ‘Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/> accessed 15 October 2026.
Pubrica Academy. Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/
Pubrica Academy, “Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/
@misc{evidence_based_analyses_to_look_at_cos_2026,
author = {{Pubrica Academy}},
title = {Cost-effectiveness evidence for radiotherapy device manufacturers: what a payer actually reads},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/data-analytics/evidence-based-analyses-to-look-at-cost-effectiveness-cost-benefit-information-clinical-data-from-rt-device-manufacturers/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Decision problem specification (fill before any analysis)
This is the first page of an economic evaluation and the one most often written last. Every line here is a CHEERS 2022 reporting item. If a line is blank, the analysis cannot be interpreted — by a reviewer or by you.
DECISION PROBLEM SPECIFICATION
Technology: ______________________ Version / configuration: __________________
1. THE DECISION
Decision-maker (hospital / regional purchaser / national HTA agency): ____________
Jurisdiction: ______________ Their published methods guide: ______________
Decision being informed: ______________________
2. POPULATION AND SETTING
Population (indication, stage, line of therapy): ______________________
Setting and level of care: ______________________
Subgroups in which the answer may differ: ______________________
3. COMPARATOR
Comparator AS ACTUALLY USED in that setting: ______________________
Source for that statement: ______________________
[ ] Confirmed this is not simply the comparator used in our clinical study
4. PERSPECTIVE AND HORIZON
Perspective: [ ] public payer [ ] healthcare sector [ ] societal [ ] other: ____
Base case if more than one is reported: ______________________
Time horizon: __________ Justification for that length: ______________________
Discount rate (costs / effects): ______ / ______ Source: ______________
Price year and currency: ______________________
5. OUTCOME
Evaluation type: [ ] cost-minimisation [ ] cost-effectiveness [ ] cost-utility
[ ] cost-benefit [ ] budget impact
Effect unit: ______________________
If QALYs: utility source: ______________ instrument: ______ valued in: ______
If NOT QALYs: what the chosen unit fails to capture: ______________________
6. INPUTS
Effectiveness source: ______________________
[ ] identified by a documented search [ ] single study [ ] model synthesis
Resource use source: ______________________
Unit cost source: ______________________
7. UNCERTAINTY
[ ] Probabilistic analysis planned iterations: __________
[ ] Cost-effectiveness acceptability curve to be reported
[ ] One-way analyses on the parameters expected to drive the result: ____________
[ ] Structural / scenario analyses: ______________________
[ ] Heterogeneity across subgroups addressed how: ______________________
8. INTERPRETATION
Threshold the deciding body applies: __________ Source: __________
[ ] We will report our ICER against that threshold, not declare cost-effectiveness
9. DECLARATIONS
Funder: ______________________ Role of sponsor in design and analysis: ________
[ ] CHEERS 2022 checklist completed and submitted with the report Pubrica AcademyWritten and maintained by the subject matter experts of Pubrica who do this work. Articles are revised when the standard underneath them moves, and each one carries the date it was last checked.
How Pubrica helps
Pubrica writes health economic evaluations to the CHEERS 2022 structure, starting from the decision problem rather than the model, so that perspective, horizon, comparator and utility source are specified before any analysis is run. Our biostatistics team builds the probabilistic uncertainty analysis and the acceptability curves that technology assessment reviewers expect, and we run the documented evidence searches that model inputs have to come from. Where the honest answer is that the evidence does not support the claim you want to make, we will tell you that before you submit.